Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach
To assess the impact of a novel molecular imaging technique, Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with...
Gespeichert in:
| Veröffentlicht in: | BJU international 2017-08, Vol.120 (2), p.197-203 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 203 |
|---|---|
| container_issue | 2 |
| container_start_page | 197 |
| container_title | BJU international |
| container_volume | 120 |
| creator | Albisinni, Simone Artigas, Carlos Aoun, Fouad Biaou, Ibrahim Grosman, Julien Gil, Thierry Hawaux, Eric Limani, Ksenija Otte, Francois-Xavier Peltier, Alexandre Sideris, Spyridon Sirtaine, Nicolas Flamen, Patrick van Velthoven, Roland |
| description | To assess the impact of a novel molecular imaging technique,
Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent.
In all, 131 consecutive patients were referred to our centre for a
Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11/131(8%) presented with persistent PSA after radical prostatectomy, while 120/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq/kg of the
Ga-(HBED-CC)-PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging.
All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72-6.7) ng/mL. Overall,
Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer in 98/131 (75%) patients. There was an impact on subsequent management in 99/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, high-intensity focussed ultrasound).
Our preliminary experience suggests that performing
Ga-PSMA PET/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients. However, larger prospective trials are needed to validate our present findings. |
| doi_str_mv | 10.1111/bju.13739 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852687462</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1852687462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1302-25a7043b164e8f2390cde5a8352fef2ebb26c06bb6e4f6541f06be50afdb76863</originalsourceid><addsrcrecordid>eNplUsFu1DAQDQhES-HAD1Q-dg_p2k7iZLlVq1KQikBikbhFjjPenSpOjO0U7d8zZXcREr54_PzevPF4suyd4NeC1rJ7mK9FURer59m5KFWZl4L_eHGK-UqdZa9jfOCcAFW9ys5kvWpEXcjzZ5frAUc0emDovDaJTZapht3p3IcpJp0gjx4MWjTMgeuCHoHpMeEWRnb19dvnmwXzU8QUppGBwxiRgjS5aRu03-2XZnJ-TtD_g5HudrNcbxYMR-Z1QhhTZL8w7djJlBk9GggHMGDEccv-L-hUh7aJuCmATo5yHVRmDpT6EcgkEfie9DCgw1GHPSn1sI8Yn56rmZuHhD1Gg3443nty02b3Jntp9RDh7XG_yL5_uN2sP-b3X-4-rW_ucyMKLnNZ6ZqXRSdUCY2VxYqbHirdFJW0YCV0nVSGq65TUFpVlcLSASqubd_VqlHFRXZ1yEu2P2eIqaVWGhgGavc0x1Y0lVRNXSpJ1MWBaqgfMYBtfUBHRbeCt0_j0NI4tH_GgbiXx7Rz56D_yzz9f_Ebj9y4ZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1852687462</pqid></control><display><type>article</type><title>Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Albisinni, Simone ; Artigas, Carlos ; Aoun, Fouad ; Biaou, Ibrahim ; Grosman, Julien ; Gil, Thierry ; Hawaux, Eric ; Limani, Ksenija ; Otte, Francois-Xavier ; Peltier, Alexandre ; Sideris, Spyridon ; Sirtaine, Nicolas ; Flamen, Patrick ; van Velthoven, Roland</creator><creatorcontrib>Albisinni, Simone ; Artigas, Carlos ; Aoun, Fouad ; Biaou, Ibrahim ; Grosman, Julien ; Gil, Thierry ; Hawaux, Eric ; Limani, Ksenija ; Otte, Francois-Xavier ; Peltier, Alexandre ; Sideris, Spyridon ; Sirtaine, Nicolas ; Flamen, Patrick ; van Velthoven, Roland</creatorcontrib><description>To assess the impact of a novel molecular imaging technique,
Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent.
In all, 131 consecutive patients were referred to our centre for a
Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11/131(8%) presented with persistent PSA after radical prostatectomy, while 120/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq/kg of the
Ga-(HBED-CC)-PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging.
All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72-6.7) ng/mL. Overall,
Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer in 98/131 (75%) patients. There was an impact on subsequent management in 99/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, high-intensity focussed ultrasound).
Our preliminary experience suggests that performing
Ga-PSMA PET/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients. However, larger prospective trials are needed to validate our present findings.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.13739</identifier><identifier>PMID: 27981732</identifier><language>eng</language><publisher>England</publisher><subject>Aged ; Clinical Decision-Making ; Gallium Radioisotopes ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnostic imaging ; Neoplasm Recurrence, Local - surgery ; Positron Emission Tomography Computed Tomography - methods ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - surgery ; Retrospective Studies</subject><ispartof>BJU international, 2017-08, Vol.120 (2), p.197-203</ispartof><rights>2016 The Authors BJU International © 2016 BJU International Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1302-25a7043b164e8f2390cde5a8352fef2ebb26c06bb6e4f6541f06be50afdb76863</citedby><cites>FETCH-LOGICAL-c1302-25a7043b164e8f2390cde5a8352fef2ebb26c06bb6e4f6541f06be50afdb76863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27981732$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Albisinni, Simone</creatorcontrib><creatorcontrib>Artigas, Carlos</creatorcontrib><creatorcontrib>Aoun, Fouad</creatorcontrib><creatorcontrib>Biaou, Ibrahim</creatorcontrib><creatorcontrib>Grosman, Julien</creatorcontrib><creatorcontrib>Gil, Thierry</creatorcontrib><creatorcontrib>Hawaux, Eric</creatorcontrib><creatorcontrib>Limani, Ksenija</creatorcontrib><creatorcontrib>Otte, Francois-Xavier</creatorcontrib><creatorcontrib>Peltier, Alexandre</creatorcontrib><creatorcontrib>Sideris, Spyridon</creatorcontrib><creatorcontrib>Sirtaine, Nicolas</creatorcontrib><creatorcontrib>Flamen, Patrick</creatorcontrib><creatorcontrib>van Velthoven, Roland</creatorcontrib><title>Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>To assess the impact of a novel molecular imaging technique,
Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent.
In all, 131 consecutive patients were referred to our centre for a
Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11/131(8%) presented with persistent PSA after radical prostatectomy, while 120/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq/kg of the
Ga-(HBED-CC)-PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging.
All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72-6.7) ng/mL. Overall,
Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer in 98/131 (75%) patients. There was an impact on subsequent management in 99/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, high-intensity focussed ultrasound).
Our preliminary experience suggests that performing
Ga-PSMA PET/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients. However, larger prospective trials are needed to validate our present findings.</description><subject>Aged</subject><subject>Clinical Decision-Making</subject><subject>Gallium Radioisotopes</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnostic imaging</subject><subject>Neoplasm Recurrence, Local - surgery</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - surgery</subject><subject>Retrospective Studies</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplUsFu1DAQDQhES-HAD1Q-dg_p2k7iZLlVq1KQikBikbhFjjPenSpOjO0U7d8zZXcREr54_PzevPF4suyd4NeC1rJ7mK9FURer59m5KFWZl4L_eHGK-UqdZa9jfOCcAFW9ys5kvWpEXcjzZ5frAUc0emDovDaJTZapht3p3IcpJp0gjx4MWjTMgeuCHoHpMeEWRnb19dvnmwXzU8QUppGBwxiRgjS5aRu03-2XZnJ-TtD_g5HudrNcbxYMR-Z1QhhTZL8w7djJlBk9GggHMGDEccv-L-hUh7aJuCmATo5yHVRmDpT6EcgkEfie9DCgw1GHPSn1sI8Yn56rmZuHhD1Gg3443nty02b3Jntp9RDh7XG_yL5_uN2sP-b3X-4-rW_ucyMKLnNZ6ZqXRSdUCY2VxYqbHirdFJW0YCV0nVSGq65TUFpVlcLSASqubd_VqlHFRXZ1yEu2P2eIqaVWGhgGavc0x1Y0lVRNXSpJ1MWBaqgfMYBtfUBHRbeCt0_j0NI4tH_GgbiXx7Rz56D_yzz9f_Ebj9y4ZQ</recordid><startdate>201708</startdate><enddate>201708</enddate><creator>Albisinni, Simone</creator><creator>Artigas, Carlos</creator><creator>Aoun, Fouad</creator><creator>Biaou, Ibrahim</creator><creator>Grosman, Julien</creator><creator>Gil, Thierry</creator><creator>Hawaux, Eric</creator><creator>Limani, Ksenija</creator><creator>Otte, Francois-Xavier</creator><creator>Peltier, Alexandre</creator><creator>Sideris, Spyridon</creator><creator>Sirtaine, Nicolas</creator><creator>Flamen, Patrick</creator><creator>van Velthoven, Roland</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201708</creationdate><title>Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach</title><author>Albisinni, Simone ; Artigas, Carlos ; Aoun, Fouad ; Biaou, Ibrahim ; Grosman, Julien ; Gil, Thierry ; Hawaux, Eric ; Limani, Ksenija ; Otte, Francois-Xavier ; Peltier, Alexandre ; Sideris, Spyridon ; Sirtaine, Nicolas ; Flamen, Patrick ; van Velthoven, Roland</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1302-25a7043b164e8f2390cde5a8352fef2ebb26c06bb6e4f6541f06be50afdb76863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Clinical Decision-Making</topic><topic>Gallium Radioisotopes</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnostic imaging</topic><topic>Neoplasm Recurrence, Local - surgery</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - surgery</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Albisinni, Simone</creatorcontrib><creatorcontrib>Artigas, Carlos</creatorcontrib><creatorcontrib>Aoun, Fouad</creatorcontrib><creatorcontrib>Biaou, Ibrahim</creatorcontrib><creatorcontrib>Grosman, Julien</creatorcontrib><creatorcontrib>Gil, Thierry</creatorcontrib><creatorcontrib>Hawaux, Eric</creatorcontrib><creatorcontrib>Limani, Ksenija</creatorcontrib><creatorcontrib>Otte, Francois-Xavier</creatorcontrib><creatorcontrib>Peltier, Alexandre</creatorcontrib><creatorcontrib>Sideris, Spyridon</creatorcontrib><creatorcontrib>Sirtaine, Nicolas</creatorcontrib><creatorcontrib>Flamen, Patrick</creatorcontrib><creatorcontrib>van Velthoven, Roland</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Albisinni, Simone</au><au>Artigas, Carlos</au><au>Aoun, Fouad</au><au>Biaou, Ibrahim</au><au>Grosman, Julien</au><au>Gil, Thierry</au><au>Hawaux, Eric</au><au>Limani, Ksenija</au><au>Otte, Francois-Xavier</au><au>Peltier, Alexandre</au><au>Sideris, Spyridon</au><au>Sirtaine, Nicolas</au><au>Flamen, Patrick</au><au>van Velthoven, Roland</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2017-08</date><risdate>2017</risdate><volume>120</volume><issue>2</issue><spage>197</spage><epage>203</epage><pages>197-203</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>To assess the impact of a novel molecular imaging technique,
Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent.
In all, 131 consecutive patients were referred to our centre for a
Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11/131(8%) presented with persistent PSA after radical prostatectomy, while 120/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq/kg of the
Ga-(HBED-CC)-PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging.
All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72-6.7) ng/mL. Overall,
Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer in 98/131 (75%) patients. There was an impact on subsequent management in 99/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, high-intensity focussed ultrasound).
Our preliminary experience suggests that performing
Ga-PSMA PET/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients. However, larger prospective trials are needed to validate our present findings.</abstract><cop>England</cop><pmid>27981732</pmid><doi>10.1111/bju.13739</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2017-08, Vol.120 (2), p.197-203 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852687462 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Aged Clinical Decision-Making Gallium Radioisotopes Humans Male Middle Aged Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnostic imaging Neoplasm Recurrence, Local - surgery Positron Emission Tomography Computed Tomography - methods Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - surgery Retrospective Studies |
| title | Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A30%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20impact%20of%2068%20Ga-prostate-specific%20membrane%20antigen%20(PSMA)%20positron%20emission%20tomography/computed%20tomography%20(PET/CT)%20in%20patients%20with%20prostate%20cancer%20with%20rising%20prostate-specific%20antigen%20after%20treatment%20with%20curative%20intent:%20preliminary%20analysis%20of%20a%20multidisciplinary%20approach&rft.jtitle=BJU%20international&rft.au=Albisinni,%20Simone&rft.date=2017-08&rft.volume=120&rft.issue=2&rft.spage=197&rft.epage=203&rft.pages=197-203&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/bju.13739&rft_dat=%3Cproquest_cross%3E1852687462%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1852687462&rft_id=info:pmid/27981732&rfr_iscdi=true |